|
Blood samples healthy controls from Sudan (n = 50)
|
0
|
50
|
|
Blood samples confirmed VL cases from Sudan (n = 30)
|
28
|
2
|
|
Skin biopsies of patients with other skin diseases from The Netherlands (n = 5)
|
0
|
5
|
|
Skin biopsies of patients with confirmed CL from Suriname (n = 27)
|
27
|
0
|
|
Skin biopsies of patients with confirmed CL from Brazil (n = 43)
|
42
|
1
|
|
Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) estimated at a 95% confidence interval (95% CI) of the NASBA-OC on different clinical samples
|
|
NASBA-OC employed on blood samples
|
|
Sensitivity
|
93.3% (95% CI: 76.5% - 98.8%)
|
|
Specificity
|
100% (95 CI: 91.1% - 100%)
|
|
PPV
|
100% (95% CI: 85.0 - 100%)
|
|
NPV
|
96.2% (95 CI: 85.7% - 99.3%)
|
|
NASBA-OC employed on skin biopsies
|
|
Sensitivity
|
98.6% (95% CI: 91.2% - 99.9%)
|
|
Specificity
|
100% (95% CI: 46.3% - 100%)
|
|
PPV
|
100% (95% CI: 93.4% - 100%)
|
|
NPV
|
83.3% (95% CI: 36.5% - 99.1%)
|
